Kleanthis G. Xanthopoulos
2013 - Regulus Therapeutics
In 2013, Kleanthis G. Xanthopoulos earned a total compensation of $2.6M as President & Chief Executive Officer at Regulus Therapeutics, a 74% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $360,000 |
|---|---|
| Option Awards | $1,676,823 |
| Salary | $600,000 |
| Other | $4,540 |
| Total | $2,641,363 |
Xanthopoulos received $1.7M in option awards, accounting for 63% of the total pay in 2013.
Xanthopoulos also received $360K in non-equity incentive plan, $600K in salary and $4.5K in other compensation.
Rankings
In 2013, Kleanthis G. Xanthopoulos' compensation ranked 2,938th out of 12,286 executives tracked by ExecPay. In other words, Xanthopoulos earned more than 76.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,938 out of 12,286 | 76th |
Division Manufacturing | 975 out of 4,612 | 79th |
Major group Chemicals And Allied Products | 256 out of 1,462 | 83rd |
Industry group Drugs | 174 out of 1,156 | 85th |
Industry Pharmaceutical Preparations | 144 out of 890 | 84th |
Source: SEC filing on April 30, 2015.
Xanthopoulos' colleagues
We found one more compensation record of an executive who worked with Kleanthis G. Xanthopoulos at Regulus Therapeutics in 2013.
2013
Neil Gibson
Regulus Therapeutics